Updates in clinical medicine: MASLD in children and adolescents
Pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly common liver disease, with a global prevalence estimated up to 7.5% and substantial concern for hepatic and extrahepatic complications even in early life. In this paper, we review recent advances in epidemiology, genetics, early-life risk factors, natural history and comorbidities, focusing on emerging data published in the last 3 years. We also outline a practical approach to the management of MASLD in children, integrating newly developed non-invasive tests. Lastly, we provide key research questions to be studied in the coming years.
Authors
- Jake P. Mann (ORCID: https://orcid.org/0000-0002-4711-9215)
- Bart G.P. Koot (ORCID: https://orcid.org/0000-0002-4350-3084)
- Ruth De Bruyne
- Christian A. Hudert
- Philip Bufler
- Sander Lefere
Institutions
- Ghent University Hospital (BE)
- Emma Kinderziekenhuis (NL)
- German Centre for Cardiovascular Research (DE)
- Amsterdam University Medical Centers (NL)
- Birmingham Women’s and Children’s NHS Foundation Trust (GB)
- Charité - Universitätsmedizin Berlin (DE)
- University of Amsterdam (NL)
Publication Details
- Journal
- Journal of Hepatology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.jhep.2026.02.016
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00